R. LaDuane Clifton, MBA, CPA

R. LaDuane Clifton, MBA, CPA

Former Chief Financial Officer and TreasureratZevra Therapeutics· In proxies 2022–2025

Pay in FY2025+164% from the year before · Zevra Therapeutics stock +7.4% the same year

R. LaDuane Clifton, MBA, CPA was paid $3.8M in FY2025 (Dec), up 164%. Zevra Therapeutics stock rose 7.4% that year.

Pay$100 in the stock at the end of FY21 → $103
Pay is from the Summary Compensation Table of each Zevra Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Zevra TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer and Treasurer2022 – Present · 4 yrStock in role +11%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?